BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 23891090)

  • 1. Acquired resistance to cetuximab is associated with the overexpression of Ras family members and the loss of radiosensitization in head and neck cancer cells.
    Saki M; Toulany M; Rodemann HP
    Radiother Oncol; 2013 Sep; 108(3):473-8. PubMed ID: 23891090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR status and EGFR ligand expression influence the treatment response of head and neck cancer cell lines.
    Jedlinski A; Ansell A; Johansson AC; Roberg K
    J Oral Pathol Med; 2013 Jan; 42(1):26-36. PubMed ID: 22643066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RAS/PI3K crosstalk and cetuximab resistance in head and neck squamous cell carcinoma.
    Rampias T; Giagini A; Siolos S; Matsuzaki H; Sasaki C; Scorilas A; Psyrri A
    Clin Cancer Res; 2014 Jun; 20(11):2933-46. PubMed ID: 24696319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition.
    Troiani T; Napolitano S; Vitagliano D; Morgillo F; Capasso A; Sforza V; Nappi A; Ciardiello D; Ciardiello F; Martinelli E
    Clin Cancer Res; 2014 Jul; 20(14):3775-86. PubMed ID: 24812410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab.
    Ather F; Hamidi H; Fejzo MS; Letrent S; Finn RS; Kabbinavar F; Head C; Wong SG
    PLoS One; 2013; 8(2):e56112. PubMed ID: 23405260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations.
    Wang Z; Martin D; Molinolo AA; Patel V; Iglesias-Bartolome R; Degese MS; Vitale-Cross L; Chen Q; Gutkind JS
    J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25099740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inactivation of HNSCC cells by 90Y-labeled cetuximab strictly depends on the number of induced DNA double-strand breaks.
    Saker J; Kriegs M; Zenker M; Heldt JM; Eke I; Pietzsch HJ; Grénman R; Cordes N; Petersen C; Baumann M; Steinbach J; Dikomey E; Kasten-Pisula U
    J Nucl Med; 2013 Mar; 54(3):416-23. PubMed ID: 23345302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance of oral squamous cell carcinoma cells to cetuximab is associated with EGFR insensitivity and enhanced stem cell-like potency.
    Ohnishi Y; Minamino Y; Kakudo K; Nozaki M
    Oncol Rep; 2014 Aug; 32(2):780-6. PubMed ID: 24926885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytotoxic properties of radionuclide-conjugated Cetuximab without and in combination with external irradiation in head and neck cancer cells in vitro.
    Eke I; Ingargiola M; Förster C; Kunz-Schughart LA; Baumann M; Runge R; Freudenberg R; Kotzerke J; Heldt JM; Pietzsch HJ; Steinbach J; Cordes N
    Int J Radiat Biol; 2014 Aug; 90(8):678-86. PubMed ID: 24597752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms underlying resistance to cetuximab in the HNSCC cell line: role of AKT inhibition in bypassing this resistance.
    Rebucci M; Peixoto P; Dewitte A; Wattez N; De Nuncques MA; Rezvoy N; Vautravers-Dewas C; Buisine MP; Guerin E; Peyrat JP; Lartigau E; Lansiaux A
    Int J Oncol; 2011 Jan; 38(1):189-200. PubMed ID: 21109940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radioresistance of K-Ras mutated human tumor cells is mediated through EGFR-dependent activation of PI3K-AKT pathway.
    Toulany M; Dittmann K; Krüger M; Baumann M; Rodemann HP
    Radiother Oncol; 2005 Aug; 76(2):143-50. PubMed ID: 16024124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined molecular targeted drug therapy for EGFR and HER-2 in head and neck squamous cell carcinoma cell lines.
    Kondo N; Tsukuda M; Sakakibara A; Takahashi H; Hyakusoku H; Komatsu M; Niho T; Nakazaki K; Toth G
    Int J Oncol; 2012 Jun; 40(6):1805-12. PubMed ID: 22344385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma.
    Braig F; Voigtlaender M; Schieferdecker A; Busch CJ; Laban S; Grob T; Kriegs M; Knecht R; Bokemeyer C; Binder M
    Oncotarget; 2016 Jul; 7(28):42988-42995. PubMed ID: 27119512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of EGFR or IGF-1R signaling enhances radiation response in head and neck cancer models but concurrent inhibition has no added benefit.
    Raju U; Molkentine DP; Valdecanas DR; Deorukhkar A; Mason KA; Buchholz TA; Meyn RE; Ang KK; Skinner H
    Cancer Med; 2015 Jan; 4(1):65-74. PubMed ID: 25355701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overcoming resistance to EGFR inhibitor in head and neck cancer: a review of the literature.
    Rabinowits G; Haddad RI
    Oral Oncol; 2012 Nov; 48(11):1085-9. PubMed ID: 22840785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TGFα and amphiregulin paracrine network promotes resistance to EGFR blockade in colorectal cancer cells.
    Hobor S; Van Emburgh BO; Crowley E; Misale S; Di Nicolantonio F; Bardelli A
    Clin Cancer Res; 2014 Dec; 20(24):6429-38. PubMed ID: 24916700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. K-RAS(V12) induces autocrine production of EGFR ligands and mediates radioresistance through EGFR-dependent Akt signaling and activation of DNA-PKcs.
    Minjgee M; Toulany M; Kehlbach R; Giehl K; Rodemann HP
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1506-14. PubMed ID: 21985943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stimulated PI3K-AKT signaling mediated through ligand or radiation-induced EGFR depends indirectly, but not directly, on constitutive K-Ras activity.
    Toulany M; Baumann M; Rodemann HP
    Mol Cancer Res; 2007 Aug; 5(8):863-72. PubMed ID: 17699110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging of epidermal growth factor receptor expression in head and neck cancer with SPECT/CT and 111In-labeled cetuximab-F(ab')2.
    van Dijk LK; Hoeben BA; Kaanders JH; Franssen GM; Boerman OC; Bussink J
    J Nucl Med; 2013 Dec; 54(12):2118-24. PubMed ID: 24136932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual targeting of EGFR and focal adhesion kinase in 3D grown HNSCC cell cultures.
    Eke I; Cordes N
    Radiother Oncol; 2011 Jun; 99(3):279-86. PubMed ID: 21704406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.